ONCOLOGY Vol 15 No 8 | Oncology

Pain Control an Issue Again

August 01, 2001

The finding by a California jury in mid-June that a state physician was guilty of elder abuse and neglect because the physician undermedicated a terminal bone cancer patient gave new impetus to the Conquering Pain Act, a bill that was introduced by

Invasive Aspergillosis in Cancer Patients

August 01, 2001

The incidence of invasive aspergillosis is increasing parallel to the intensity of immunosuppressive and myelosuppressive anticancer treatments. Successful management is linked to an understanding of the

Combined-Modality Staging for Localized Adenocarcinoma of the Prostate

August 01, 2001

The goal of identifying a set of pretreatment risk-stratifying factors for patients with localized prostate cancer is to be able to individualize treatment and optimize patient selection for clinical trials. Low-risk patients are most likely

Combined-Modality Staging for Localized Adenocarcinoma of the Prostate

August 01, 2001

The goal of identifying a set of pretreatment risk-stratifying factors for patients with localized prostate cancer is to be able to individualize treatment and optimize patient selection for clinical trials. Low-risk patients are most likely

Current Clinical Trials of the Anti-VEGF Monoclonal Antibody Bevacizumab

August 01, 2001

Given the well-established role of angiogenesis (or new blood vessel formation) in tumor growth and metastasis, antiangiogenic therapy, a concept first proposed by Dr. Judah Folkman,[1] has become increasingly recognized as a promising

Combined-Modality Staging for Localized Adenocarcinoma of the Prostate

August 01, 2001

The goal of identifying a set of pretreatment risk-stratifying factors for patients with localized prostate cancer is to be able to individualize treatment and optimize patient selection for clinical trials. Low-risk patients are most likely

Invasive Aspergillosis in Cancer Patients

August 01, 2001

The incidence of invasive aspergillosis is increasing parallel to the intensity of immunosuppressive and myelosuppressive anticancer treatments. Successful management is linked to an understanding of the

Diagnosis and Treatment of Thrombocythemia in Myeloproliferative Disorders

August 01, 2001

Myeloproliferative disorders originate in the clonal expansion of a transformed pluripotential hematopoietic progenitor cell. This results in a group of syndromes that include polycythemia vera, essential thrombocythemia,

Invasive Aspergillosis in Cancer Patients

August 01, 2001

The incidence of invasive aspergillosis is increasing parallel to the intensity of immunosuppressive and myelosuppressive anticancer treatments. Successful management is linked to an understanding of the

Combined-Modality Staging for Localized Adenocarcinoma of the Prostate

August 01, 2001

The goal of identifying a set of pretreatment risk-stratifying factors for patients with localized prostate cancer is to be able to individualize treatment and optimize patient selection for clinical trials. Low-risk patients are most likely

Nonsteroidal and Steroidal Aromatase Inhibitors in Breast Cancer

August 01, 2001

Anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are members of the third generation of aromatase inhibitors that has now replaced aminoglutethimide (Cytadren), the progestins, and tamoxifen